GI Signals · Trends

The digest, over time.

Charts from the 2 published issues so far: how selective it stays, which areas are busy, and what moves the standard of care.

01 / OVER TIME

How selective it stays

Papers surfaced as a share of papers screened, each week (oldest first). It should stay low and steady.

0%10%Surfaced %7%06/24/269%07/12/26
Fills in as more issues publish.
02 / OVER TIME

Which areas are busy

Surfaced papers by subspecialty, week by week (oldest at left). A busy section or a quiet stretch shows up week to week.

06/24/26
07/12/26
IBD
5
1
Hepatology
2
5
Esophagus/Reflux
2
2
Pancreas/Biliary
3
2
Endoscopy
5
5
Motility
4
Colorectal
5
2
Nutrition
3
Fills in as more issues publish.
03 / OVER TIME

How much each week shifts the standard

Mean standard-shift by week, oldest first (1 reinforces current practice, 5 challenges it). A busy week reads differently from a quiet one.

12345Mean shift3.306/24/262.207/12/26
Fills in as more issues publish.
04 / OVER TIME

Which journals show up most

Cumulative surfaced papers by journal: the journals that carry the signal, week after week.

Lancet GH6
J Hepatology4
GIE4
Inflammatory bowel diseases4
Gastroenterology3
Endoscopy3
United European gastroenterology J3
BMJ2
Fills in as more issues publish.
05 / OVER TIME

The run so far

One tile per week (oldest first): how many papers surfaced and the spread of their signal scores.

06/24/26 · #1
29surfaced
score 39 to 78
07/12/26 · #2
17surfaced
score 39 to 77
Fills in as more issues publish.
06 / THIS ISSUE

The signal map

Every surfaced paper placed by study rigor and novelty; dot size is journal standing. Top right is the week's must-read.

matters mostlower rigorhigher rigor →Reinforces → challenges the standard
07 / THIS ISSUE

What drove each score

The top papers, each split into the four scoring parts, so you can see why a paper ranked without opening its card.

Long term follow-up from the Barrett's esophagus screening trial 3 (BEST3) demonstrates high negative predictive value of capsule-sponge-Trefoil-factor-3 (TFF3) test for esophageal adenocarcinoma.77
Computer-aided quality assurance versus standard colonoscopy: A systematic review and meta-analysis of randomized-controlled trials.63
Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial.61
IgA-Enriched Phenotype Predicts Liver-Related Events in MASLD.60
Artificial intelligence-assisted detection and optical differentiation of colorectal lesions in Lynch syndrome surveillance (CADLY2): a multicentre, open-label, randomised controlled superiority trial.59
Contemporary hormonal contraception and colorectal cancer in premenopausal women: nationwide cohort study.58
A machine learning approach to non-invasive prediction of hepatic decompensation in compensated advanced chronic liver disease: the CIRI model.57
Cryptogenic steatotic liver disease: a lean phenotype associated with increased liver-related mortality.56
Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.56
Advanced and Salvage Techniques for Difficult Biliary Cannulation in ERCP: A Randomized Trial of Outcomes and Efficacy.56
Meta-Analysis: Chronic Gastrointestinal Symptoms and Comorbidities in Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders.54
Curriculum on management of acute upper gastrointestinal bleeding: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement.53
Study rigorShiftPractice relevanceJournal standing